WO2004082675A8 - Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate - Google Patents

Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate

Info

Publication number
WO2004082675A8
WO2004082675A8 PCT/JP2004/003589 JP2004003589W WO2004082675A8 WO 2004082675 A8 WO2004082675 A8 WO 2004082675A8 JP 2004003589 W JP2004003589 W JP 2004003589W WO 2004082675 A8 WO2004082675 A8 WO 2004082675A8
Authority
WO
WIPO (PCT)
Prior art keywords
methylpropanethioate
ethylbutyl
cyclohexyl
carbonyl
phenyl
Prior art date
Application number
PCT/JP2004/003589
Other languages
French (fr)
Other versions
WO2004082675A1 (en
Inventor
Yasuo Urata
Tomohiro Ishikawa
Original Assignee
Japan Tobacco Inc
Yasuo Urata
Tomohiro Ishikawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Yasuo Urata, Tomohiro Ishikawa filed Critical Japan Tobacco Inc
Priority to AU2004222436A priority Critical patent/AU2004222436A1/en
Priority to JP2006507671A priority patent/JP2006520810A/en
Priority to EP04721354A priority patent/EP1603554A1/en
Priority to MXPA05009976A priority patent/MXPA05009976A/en
Priority to CA002519458A priority patent/CA2519458A1/en
Priority to BRPI0408442-0A priority patent/BRPI0408442A/en
Publication of WO2004082675A1 publication Critical patent/WO2004082675A1/en
Priority to NO20054739A priority patent/NO20054739L/en
Publication of WO2004082675A8 publication Critical patent/WO2004082675A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention is directed to a method of increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate by administration of a therapeutically effective amount of the drug with food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl] 2-methylpropanethioate and a pharmaceutically acceptable carrier, prescribing information, and a container, wherein the prescribing information includes advice to a patient regarding administration of the drug with food to improve bioavailability.
PCT/JP2004/003589 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate WO2004082675A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2004222436A AU2004222436A1 (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
JP2006507671A JP2006520810A (en) 2003-03-17 2004-03-17 Method for increasing the oral absorption of S- [2-([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
EP04721354A EP1603554A1 (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
MXPA05009976A MXPA05009976A (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate.
CA002519458A CA2519458A1 (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
BRPI0408442-0A BRPI0408442A (en) 2003-03-17 2004-03-17 method for increasing the oral bioavailability of s- [2 - ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanothioate
NO20054739A NO20054739L (en) 2003-03-17 2005-10-14 Method for increasing oral bioavailability of S-2 '- ("1- (2-ethylbutyl) cyclohexylcarbonylamino) phenyl] -2-methylpropanethioate

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45529303P 2003-03-17 2003-03-17
US60/455,293 2003-03-17
US46052103P 2003-04-04 2003-04-04
US60/460,521 2003-04-04
US47720203P 2003-06-10 2003-06-10
US60/477,202 2003-06-10

Publications (2)

Publication Number Publication Date
WO2004082675A1 WO2004082675A1 (en) 2004-09-30
WO2004082675A8 true WO2004082675A8 (en) 2005-11-03

Family

ID=33033150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/003589 WO2004082675A1 (en) 2003-03-17 2004-03-17 Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate

Country Status (11)

Country Link
US (2) US7276536B2 (en)
EP (1) EP1603554A1 (en)
JP (1) JP2006520810A (en)
KR (1) KR20050110017A (en)
AU (1) AU2004222436A1 (en)
BR (1) BRPI0408442A (en)
CA (1) CA2519458A1 (en)
CO (1) CO5700729A2 (en)
MX (1) MXPA05009976A (en)
NO (1) NO20054739L (en)
WO (1) WO2004082675A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2004082675A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (en) * 2003-05-02 2015-08-01 Japan Tobacco Inc Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007142810A2 (en) 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20080058408A1 (en) 2006-05-19 2008-03-06 Rogowski Roberta L Low-dose doxepin for treatment of sleep disorders in elderly patients
US20100227916A1 (en) * 2006-05-19 2010-09-09 Somaxon Pharmaceuticals, Inc N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US7915307B2 (en) * 2006-07-20 2011-03-29 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
EP2373344B1 (en) * 2008-12-08 2016-03-30 F. Hoffmann-La Roche AG Combined drug administration
JP5676005B2 (en) 2010-11-04 2015-02-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ A composition comprising S- [2-([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate and croscarmellose sodium
CN105164276B (en) 2013-03-27 2020-01-14 豪夫迈·罗氏有限公司 Genetic markers for predicting responsiveness to treatment
MX2017000582A (en) 2014-07-30 2017-04-27 Hoffmann La Roche Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent.

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576830A (en) 1966-08-12 1971-04-27 Sumitomo Chemical Co Amides containing sulfur
JPS4735786U (en) 1971-05-10 1972-12-20
US4346277A (en) 1979-10-29 1982-08-24 Eaton Corporation Packaged electrical heating element
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4740438A (en) 1986-12-10 1988-04-26 Eastman Kodak Company Organic disulfides as image dye stabilizers
US4853319A (en) 1986-12-22 1989-08-01 Eastman Kodak Company Photographic silver halide element and process
JP2569746B2 (en) 1987-08-20 1997-01-08 日産化学工業株式会社 Quinoline mevalonolactones
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
JPH01278543A (en) 1988-04-30 1989-11-08 Sanshin Chem Ind Co Ltd Rubber composition
JPH01321432A (en) 1988-06-22 1989-12-27 Konica Corp Silver halide photographic sensitive material
JPH0223338A (en) 1988-07-12 1990-01-25 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
US5118583A (en) 1988-10-12 1992-06-02 Mitsubishi Paper Mills Limited Processing composition for printing plate
DE3835198A1 (en) 1988-10-15 1990-04-19 Bayer Ag METHOD FOR PRODUCING RUBBER VULCANISES WITH REDUCED HYSTERESIS LOSSES AND FORM BODIES FROM SUCH VULCANISTS
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
JPH03226750A (en) 1990-01-31 1991-10-07 Konica Corp Silver halide color photographic sensitive material
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
FR2665450B1 (en) 1990-08-01 1994-04-08 Rhone Poulenc Chimie PROCESS FOR THE PREPARATION OF AQUEOUS COPOLYMER DISPERSIONS.
GB9017710D0 (en) 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
GB9017711D0 (en) 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
GB9120131D0 (en) 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments.
US5519001A (en) 1991-12-19 1996-05-21 Southwest Foundation For Biomedical Research CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
US5219721A (en) 1992-04-16 1993-06-15 Eastman Kodak Company Silver halide photographic emulsions sensitized in the presence of organic dichalcogenides
US5217859A (en) 1992-04-16 1993-06-08 Eastman Kodak Company Aqueous, solid particle dispersions of dichalcogenides for photographic emulsions and coatings
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5350667A (en) 1993-06-17 1994-09-27 Eastman Kodak Company Photographic elements containing magenta couplers and process for using same
IL110151A (en) 1993-06-30 1998-10-30 Sankyo Co Amide derivatives and pharmaceutical compositions containing them
AU7006094A (en) 1993-06-30 1995-01-24 Wellcome Foundation Limited, The Anti-atherosclerotic diaryl compounds
US5446207A (en) 1993-09-01 1995-08-29 Harbor Branch Oceanographic Institution, Inc. Anti-dyslipidemic agents
US5459154A (en) 1993-11-08 1995-10-17 American Home Products Corporation N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
US5405969A (en) 1993-12-10 1995-04-11 Eastman Kodak Company Manufacture of thioether compounds
JP3304189B2 (en) 1994-03-18 2002-07-22 マツダ株式会社 Molding rubber composition containing vulcanized scrap rubber and method for producing the same
US5654134A (en) 1994-05-18 1997-08-05 Fuji Photo Film Co., Ltd. Silver halide emulsion
DE4428457C1 (en) 1994-08-11 1995-10-05 Bayer Ag Shaped, paraffin contg. mastification agent for synthetic rubbers
US6001555A (en) 1994-09-23 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
WO1996015141A1 (en) 1994-11-12 1996-05-23 Lg Chemical Ltd. Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents
CA2165918A1 (en) 1994-12-26 1996-06-27 Koichi Katsuyama Diphenyl disulfide compounds
WO1996030761A1 (en) 1995-03-27 1996-10-03 Warner-Lambert Company Method and apparatus for simultaneously testing a plurality of compounds to detect their activity
SK284202B6 (en) 1995-07-17 2004-10-05 Warner-Lambert Company crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole- 1-heptanoic acid hemi calcium salt (atorvastatin)
JPH0959155A (en) 1995-08-23 1997-03-04 Kaken Pharmaceut Co Ltd Cholesteryl ester transfer reaction inhibitor
DE19610932A1 (en) 1996-03-20 1997-09-25 Bayer Ag 2-aryl substituted pyridines
DE19627431A1 (en) 1996-07-08 1998-01-15 Bayer Ag Heterocyclically fused pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
ES2127690B1 (en) 1996-08-02 2000-01-01 Univ Granada PROCEDURES FOR OBTAINING (+) - PUUPEHENONE FROM BICYCLE TERPENOIDS.
CN1238764A (en) 1996-11-27 1999-12-15 美国辉瑞有限公司 ApoB-secretion/MTP inhibitory amides
DE19704243A1 (en) 1997-02-05 1998-08-06 Bayer Ag New 2-amino-substituted pyridines
JP2894445B2 (en) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Compounds effective as CETP activity inhibitors
DE19709125A1 (en) 1997-03-06 1998-09-10 Bayer Ag Substituted quinolines
JPH10287662A (en) 1997-04-08 1998-10-27 Kitasato Inst:The Fo-5637a and b substance, and their production
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
WO1999041237A1 (en) 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6692909B1 (en) 1998-04-01 2004-02-17 Whitehead Institute For Biomedical Research Coding sequence polymorphisms in vascular pathology genes
GT199900147A (en) 1998-09-17 1999-09-06 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000018721A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000018723A1 (en) 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
CN1338944A (en) 1998-12-23 2002-03-06 G.D.瑟尔有限公司 Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
JP2002533409A (en) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー Combination of cholesteryl ester transfer protein inhibitor and bile acid sequestrant for cardiovascular applications
ES2201822T3 (en) 1998-12-23 2004-03-16 G.D. Searle Llc COMBINATIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTER OF CHOLESTERILE AND OF NICOTINIC ACID DERIVATIVES FOR CARDIOVASCULAR INDICATIONS.
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US6458852B1 (en) 1999-09-23 2002-10-01 G.D. Searle & Co. Use of substituted N, N-bis-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
HN2000000203A (en) 1999-11-30 2001-06-13 Pfizer Prod Inc PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED.
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EA200301139A1 (en) * 2001-06-21 2004-12-30 Пфайзер Продактс Инк. SELF-EMULATING PREPARATIONS OF THE INHIBITORS OF CHOLESTEROL ETHERUM PROTECTIVE
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
SI1603553T1 (en) * 2003-03-17 2012-03-30 Japan Tobacco Inc Pharmaceutical compositions of cetp inhibitors
WO2004082675A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (en) * 2003-05-02 2015-08-01 Japan Tobacco Inc Combination comprising s-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino)phenyl)2-methylpropanethioate and an hmg coa reductase inhibitor

Also Published As

Publication number Publication date
NO20054739L (en) 2005-12-14
US7276536B2 (en) 2007-10-02
JP2006520810A (en) 2006-09-14
WO2004082675A1 (en) 2004-09-30
MXPA05009976A (en) 2005-11-04
CA2519458A1 (en) 2004-09-30
CO5700729A2 (en) 2006-11-30
BRPI0408442A (en) 2006-04-04
NO20054739D0 (en) 2005-10-14
KR20050110017A (en) 2005-11-22
AU2004222436A1 (en) 2004-09-30
EP1603554A1 (en) 2005-12-14
US20040242683A1 (en) 2004-12-02
US20080045599A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2004082675A8 (en) Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
ZA200703532B (en) Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
IN2015DN01132A (en)
EP2258362A3 (en) Titration dosing regimen for controlled release tramadol
GEP20074047B (en) Pramipexole once-daily dosage form
AU2003272590A1 (en) Method for ophtalmic administration of medicament
AU4334700A (en) Pharmaceutical dosage form for pulsatile delivery of methylphenidate
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
IL179719A0 (en) Process for preparation of amorphous form of drug
WO2007098479A3 (en) Localized insulin delivery for bone healing
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2000078294A3 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
WO2004032866A3 (en) Therapeutic formulations
AU2003243439A1 (en) Medical device for intra-lumenal delivery of pharmaceutical agents
RS98704A (en) New pharmaceutical compositions containing flibanserin polymorpha
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
WO2006023497A3 (en) Intranasal delivery of antipsychotic drugs
AU2003246567A1 (en) Administration form for the oral administration of active substances, vitamins, and/or nutrients
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2006064228A3 (en) Thiazolopyramidine compounds for the modulation of chemokine receptor activity
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
AU2003257589A1 (en) Remedy for integration dysfunction syndrome
UA95601C2 (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester-methanesulphonate and pharmaceutical composition comprising thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 170750

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501652

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009976

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2519458

Country of ref document: CA

Ref document number: 1020057017446

Country of ref document: KR

Ref document number: 2006507671

Country of ref document: JP

Ref document number: 2004222436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048074442

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004721354

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004222436

Country of ref document: AU

Date of ref document: 20040317

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 542853

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2004222436

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/08160

Country of ref document: ZA

Ref document number: 200508160

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1200501486

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 05105280

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2664/CHENP/2005

Country of ref document: IN

Ref document number: 2005131951

Country of ref document: RU

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWP Wipo information: published in national office

Ref document number: 1020057017446

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004721354

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408442

Country of ref document: BR

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWW Wipo information: withdrawn in national office

Ref document number: 2004721354

Country of ref document: EP